Nilotinib hydrochloride dihydrate

Nilotinib hydrochloride dihydrate is the medically approved salt form of nilotinib, used to treat Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML). It functions as a selective tyrosine kinase inhibitor, targeting the abnormal BCR-ABL protein that drives the uncontrolled growth of white blood cells in CML. This form improves the drug’s solubility and stability, making it suitable for oral use in clinical settings, especially in patients resistant or intolerant to earlier treatments like imatinib. It is grouped under the following drug class(es): Antineoplastic agents. Its therapeutic use is listed as antineoplastics. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Nilotinib monohydrochloride dihydrate. Its PubChem CID is 67323320.

CAS No 923289-71-8
Molecular Formula C28H27ClF3N7O3
Molecular Weight 602.0 g/mol
Synonyms 4-methyl-N-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]benzamide;dihydrate;hydrochloride

Frequently Asked Questions